Biocon Biologics’ facility has received a certificate of GMP compliance for Bevacizumab from the representative European inspection authority — Health Products Regulatory Authority (HPRA), Ireland.
Biocon, a significant player in the biotechnology industry, said on Friday that its Biocon Biologics facility in Bengaluru has been granted a Certificate of GMP Compliance for the production of a biosimilar drug called bevacizumab.
The biosimilar is a medication that is used to treat various malignancies and eye conditions.
The spokesman claims that last year, this (B3) factory, one of India’s largest monoclonal antibody (mAb) production facilities, received EU GMP Certification for producing biosimilar Trastuzumab. Biocon Biologics is a division of Biocon Ltd.
Last year, the biosimilar Trastuzumab, a targeted cancer drug also known as Herceptin, Herzuma, and Ontruzant, was approved by the same institution.